BSD Medical Corporation  

(Public, NASDAQ:BSDM)   Watch this stock  
Find more results for BSDM
1.34
+0.14 (11.67%)
May 23 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.18 - 1.35
52 week 0.76 - 2.41
Open 1.20
Vol / Avg. 0.00/243,409.00
Mkt cap 39.87M
P/E     -
Div/yield     -
EPS -0.28
Shares 29.75M
Beta 0.82
Inst. own 6%
Apr 5, 2013
Q2 2013 BSD Medical Corp Earnings Release
Mar 6, 2013
BSD Medical Corp Investor & Analyst Update Conference Call
More events from DailyFinance »    

Key stats and ratios

Q1 (Feb '13) 2012
Net profit margin -227.21% -384.35%
Operating margin -227.58% -386.89%
EBITD margin - -379.57%
Return on average assets -58.21% -42.68%
Return on average equity -63.37% -44.76%
Employees 48 -
Carbon Disclosure Rating - -

Address

2188 West 2200 South
SALT LAKE CITY, UT 84119
United States - Map
+1-801-9725555 (Phone)
+1-801-9725930 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money
Discussion Group - Google Finance

Description

BSD Medical Corporation (BSD) develops, manufactures, markets and services systems to treat cancer and delivers using focused radiofrequency (RF) and microwave energy. BSD business focuses to commercialize the products for the treatment of cancer and to expand the products to treat other diseases and medical conditions. The Company�s product line for cancer therapy offers hospitals and clinics a solution for thermal treatment of cancer using microwave/RF systems. It uses microwave thermal therapy for the treatment of symptoms associated with enlarged prostate. Its product line includes systems that have been designed to offer a range of thermal treatment systems for the treatment of cancer, including both ablation and hyperthermia treatment systems. Its hyperthermia cancer treatment systems are used to treat cancer with heat (hyperthermia). In January 2013, it East Coast academic medical center (the Center) purchased a BSD-500 Hyperthermia System (BSD-500).

Officers and directors

Timothy C. McQuay Independent Chairman of the Board
Age: 61
Bio & Compensation  - Reuters
Harold R. Wolcott President, Director
Age: 66
Bio & Compensation  - Reuters
William S. Barth Chief Financial Officer, Corporate Secretary
Age: 62
Bio & Compensation  - Reuters
Gerhard W. Sennewald Ph.D. Director
Age: 76
Bio & Compensation  - Reuters
Douglas P. Boyd Ph.D. Independent Director
Age: 71
Bio & Compensation  - Reuters
Damian E. Dupuy M.D. Independent Director
Age: 50
Bio & Compensation  - Reuters
Michael Nobel Ph.D. Independent Director
Age: 72
Bio & Compensation  - Reuters
Steven G. Stewart Independent Director
Age: 64
Bio & Compensation  - Reuters